The generation of long-lived high-affinity antibodies after microbial infection or vaccine induction requires precise control of the germinal center (GC) reaction. Follicular helper T cells (T FH cells) are specialized effector CD4 + T cells that provide help for GC formation and induce GC B cells to develop protective antibody responses to invading pathogens. Bcl-6, a proto-oncoprotein and transcriptional repressor that belongs to the BTB-POZ ('bric-a-bric, tramtrack, broad complex-poxvirus zinc finger') family, has been identified as the central transcription factor that controls T FH differentiation and associated GC responses [1] [2] [3] . Because Bcl-6 deficiency can result in increased susceptibility to chronic infection, while its excessive expression is associated with autoimmunity and lymphocytic transformation, precise control of Bcl-6 expression during T cell differentiation represents an essential component of the T FH cell response 4 . Moreover, Foxp3 + follicular regulatory T cells (T FR cells) that inhibit GC responses also require Bcl-6 expression for their differentiation and suppressive activity [5] [6] [7] . However, in contrast to insight into the molecular elements that regulate Bcl-6 expression in GC B cells 4 , the mechanisms that govern Bcl-6 expression by both T FH cells and T FR cells are poorly understood.
The generation of long-lived high-affinity antibodies after microbial infection or vaccine induction requires precise control of the germinal center (GC) reaction. Follicular helper T cells (T FH cells) are specialized effector CD4 + T cells that provide help for GC formation and induce GC B cells to develop protective antibody responses to invading pathogens. Bcl-6, a proto-oncoprotein and transcriptional repressor that belongs to the BTB-POZ ('bric-a-bric, tramtrack, broad complex-poxvirus zinc finger') family, has been identified as the central transcription factor that controls T FH differentiation and associated GC responses [1] [2] [3] . Because Bcl-6 deficiency can result in increased susceptibility to chronic infection, while its excessive expression is associated with autoimmunity and lymphocytic transformation, precise control of Bcl-6 expression during T cell differentiation represents an essential component of the T FH cell response 4 . Moreover, Foxp3 + follicular regulatory T cells (T FR cells) that inhibit GC responses also require Bcl-6 expression for their differentiation and suppressive activity [5] [6] [7] . However, in contrast to insight into the molecular elements that regulate Bcl-6 expression in GC B cells 4 , the mechanisms that govern Bcl-6 expression by both T FH cells and T FR cells are poorly understood.
The differentiation of T FH cells in vivo can be divided into several stages that include initiation, maintenance and full polarization 8 . This process depends on early upregulation of Bcl-6 expression during T cell activation and T FH cell commitment, followed by continued enhanced Bcl-6 expression during the maintenance and polarization phases of the T FH cell response 9 . Although engagement of the costimulatory receptor ICOS represents a key event in a process that culminates in Bcl-6 expression and acquisition of the T FH and T FR phenotypes, the essentials of this specialized inductive pathway have not been clarified.
The binding of ICOS by its ligand ICOSL expressed by antigenpresenting cells results in recruitment of the phosphatidylinositol-3-OH kinase (PI(3)K) signaling complex that consists of a regulatory p85α subunit and a catalytic p110 component. Recruitment of PI(3)K to ICOS is an essential step in T FH differentiation, as mutations of sequence encoding the ICOS cytoplasmic tail that abrogate recruitment of PI(3)K impair the generation of T FH cells and GC responses 10 . Although deficient expression of the component p110δ impairs the migration of T FH cells to follicles 11, 12 , the ICOS-dependent upregulation of Bcl-6 expression and development of CXCR5 + T FH -like cells proceed normally [11] [12] [13] . In contrast, the contribution of the p85α component of PI(3)K to Bcl-6 expression and the development of both T FH cells and T FR cells remains unclear. Because p85α regulates the activity and localization of intracellular proteins [14] [15] [16] , we sought to determine whether an interaction between p85α and downstream intracellular protein(s) in CD4 + T cells after stimulation via ICOS might contribute to the Bcl-6-dependent T FH and T FR cell program.
The phosphoprotein osteopontin (OPN) is expressed in activated T cells [17] [18] [19] [20] [21] [22] [23] . Although dysregulated expression of OPN has been associated with a broad spectrum of T FH cell-associated autoimmune diseases and strongly correlates with autoantibody production [17] [18] [19] [20] [21] [22] [23] , the precise contribution of OPN to T FH differentiation is uncertain. OPN is expressed as either a secreted isoform (OPN-s) or intracellular isoform (OPN-i) that result from the use of different translation-initiation sites of the gene encoding OPN (Spp1) 17 . To clarify the contribution of each OPN isoform to the regulation of T FH cell responses, we generated knock-in mice that expressed only OPN-i and compared them with wild-type mice that expressed both isoforms or with OPN-deficient mice that expressed neither OPN isoform. We found that OPN-i functioned as a positive regulator of the differentiation of both T FH cells and T FR cells by enhancing the stability of Bcl-6 protein, and we identified the p85α-OPN-i complex as a critical molecular bridge that coupled engagement of ICOS to sustained responses by T FH cells and T FR cells that combined to regulate the GC antibody response.
RESULTS

OPN-i expression is essential for T FH and T FR differentiation
We first analyzed expression of Spp1 mRNA and OPN protein in various CD4 + T cell subsets after immunization of mice with keyhole limpet hemocyanin (KLH) precipitated in complete Freund's adjuvant (CFA). We noted that OPN was expressed more abundantly by the CD4 + T FH and T FR subsets than by other CD4 + T cell subsets ( Fig. 1a and Supplementary Fig. 1 ). This suggested a potential contribution of OPN to the development of these T FH and T FR cells.
To define the contribution of the OPN isoforms, we generated mice bearing a mutated Spp1 allele with deletion of nucleotides in exon 2 of Spp1 that encode an amino-terminal signal sequence 17 and with insertion of a loxP-flanked stop sequence upstream of this deletion mutation (Spp1 flstop ), which was knocked into the Spp1 locus. In this system, recombination mediated by Cre recombinase and loxP induces expression of the OPN-i isoform 17 after excision of the 'stop' cassette ( Supplementary Fig. 2a) . Crossing of Spp1 flstop mice with EIIa-Cre mice, which express Cre from the adenovirus EIIa promoter during embryonic development, resulted in the generation of Spp1 flstop Cre + mice (called 'OPN-i-knock-in' (OPN-i-KI) mice here), which expressed intracellular OPN, and Spp1 flstop Cre − mice (called 'OPN-knockout' (OPN-KO) mice here), which did not express either OPN-i or OPN-s. Mice of both genotypes were developmentally indistinguishable from their wild-type littermates, and PCR analysis confirmed expression of the Spp1 flstop alleles at the Spp1 locus (Supplementary Fig. 2b ). Secreted OPN was not detectable in supernatants of freshly isolated or activated T cells, dendritic cells (DCs), macrophages or natural killer cells from either OPN-i-KI mice or OPN-KO mice ( Supplementary  Fig. 2c) . Moreover, immunoblot analysis showed equivalent intracellular expression of OPN protein in unfractionated splenocytes from OPN-i-KI mice and wild-type mice (Supplementary Fig. 2d ). Expression of OPN-i by plasmacytoid DCs is essential for the efficient production of interferon-α (IFN-α) after ligation of Toll-like receptors, but expression of OPN-s is not 21 . As an additional control, plasmacytoid DCs obtained from OPN-i-KI and wild-type mice and activated with the dinucleotide CpG expressed similar levels of IFN-α, while plasmacytoid DCs from OPN-KO mice expressed no IFN-α (Supplementary Fig. 2e) , which confirmed the functional phenotype of OPN-i-KI mice.
We next investigated the contribution of OPN-i to T FH and T FR differentiation by comparing OPN-i-KI mice with transgenic expression of the OT-II (ovalbumin (OVA)-specific) T cell antigen receptor (TCR) with OT-II mice and OT-II OPN-KO mice. We immunized these mice with NP 13 -OVA (13 molecules of the hapten NP (4-hydroxy-3-nitrophenyl) linked to OVA) to induce antigen-specific CD4 + T cell responses. Total and high-affinity antibody responses were 80-90% lower in OT-II OPN-KO mice than in OT-II mice, while antibody titers in OT-II OPN-i-KI mice were similar to those of OT-II mice (Fig. 1b) . Although the activation of T cells was not obviously impaired in OT-II OPN-KO mice relative to that in OT-II and OT-II OPN-i-KI mice, as judged by expression of the activation and memory marker CD44 (Supplementary Fig. 3a) , OT-II OPN-KO mice displayed defective formation of T FH cells, T FR cells (but not Foxp3 + regulatory T cells (T reg cells)) and GC B cells (Fig. 1c,d and Supplementary Fig. 3a) . These findings suggested that expression of OPN-i was essential for the formation of both T FH cells and T FR cells and for T FH cell-associated high-affinity antibody responses. Fig. 1 ) from C57BL/6J mice (n = 16) 3 d after injection of KLH in CFA; mRNA results were normalized to that of the control gene Rps18 (encoding ribosomal protein S18) and are presented relative to those of naive T cells (T N ), set as (Fig. 2a,b) Fig. 3d ).
In contrast, the frequency of V β 5 + CD4 + T cells expressing IFN-γ, Fig. 3e ). In addition, OPN-KO CD4 + T cells differentiated into induced T reg cells with suppressive activity similar to that of wild-type and OPN-i-KI CD4 + T cells (Supplementary Fig. 4a,b) . (Fig. 2g) , which suggested that the magnitude of T FR cell-mediated suppression was dependent on the extent of T FH cell-driven antibody responses. Together these results indicated that OPN-i expression was required for the generation of functional T FR cells.
OPN-i deficiency impairs Bcl-6 protein expression
Because the transcription factor Bcl-6 is critical for the differentiation of T FH cells and T FR cells [6] [7] [8] , we sought to determine whether the impaired follicular T cell response of OPN-KO CD4 + T cells was associated with reduced Bcl-6 expression. Flow cytometry and immunoblot analysis of Bcl-6 expression during the development of T FH cells in vivo in wild-type mice showed that Bcl-6 was detectable by day 1 after immunization with KLH, peaked at day 7.5 and waned by day 10 (Fig. 3a,b and Supplementary Figs. 1 and 4e) , consistent with a published study 24 . Expression of Bcl-6 in T FR cells followed similar kinetics, although its expression in these cells was lower than that in T FH cells (Fig. 3a,b) . OPN deficiency did not alter the expression of Bcl6 mRNA or Prdm1 mRNA and did not impair early expression of Bcl-6 protein by OPN-KO CD4 + T cells (within ~2 d) ( Fig. 1 ) from OPN-i-KI mice (n = 3-7 per time point) at days 3-11 after immunization with KLH in CFA; results (normalized as in Fig. 1a ) are presented relative to those of T reg cells at day 3, set as 1. *P < 0.05 and **P < 0.01 (unpaired two-tailed Student's t-test). Data are representative of two independent experiments (mean and s.e.m. in b,d,e). Fig. 3a-d and Supplementary Fig. 1 ). We also observed that the expression of Spp1 mRNA and OPN and Bcl-6 protein followed similar kinetics in OPN-i-KI CD4 + T cells ( Fig. 3e and Supplementary  Fig. 4e ). These findings suggested that although OPN-i did not regulate transcription of Bcl6, it might affect the expression of Bcl-6 protein during differentiation into T FH cells and T FR cells.
ICOS costimulation promotes interaction between OPN-i and p85a
Costimulation via ICOS is essential for the induction and maintenance of Bcl-6 expression during the differentiation of T FH cells and is required for T FR cell 5, 25, 26 . Because of the congruent expression of OPN-i and Bcl-6 in T FH and T FR cells and reduced expression of Bcl-6 protein in the few CXCR5 + PD-1 + T FH cells generated by OPN-KO mice, we investigated the possibility that OPN-i mediates ICOS-induced Bcl-6 expression. Gene-profile analysis of CD4 + T cells 8 h after ligation of ICOS and the receptor CD3 identified ~210 genes, including Spp1, that were significantly upregulated relative to their expression in cells that underwent ligation of CD3 alone (P < 0.01; Supplementary Fig. 5a ). Pathway analysis of these genes (with Ingenuity software) revealed that these genes encode products involved with many biological functions associated with T cell activation, antibody production and with systemic autoimmune disease ( Supplementary Fig. 5b,c) . We confirmed upregulation of the expression of Spp1 mRNA and OPN protein by costimulation of CD4 + T cells with anti-ICOS and anti-CD3 relative to their expression in cells stimulated with anti-CD3 alone (Fig. 4a,b) . After immunization with KLH, Icos −/− CD4 + T cells did not upregulate the expression of OPN and Bcl-6 protein compared with their expression in wild-type CD4 + T cells (Fig. 4c) .
We also observed impaired upregulation of the expression of OPN and Bcl-6 protein in effector CD25 − CD44 hi GITR − CD4 + T cells and regulatory CD25 + CD44 hi GITR + CD4 + T cells obtained from OT-II Icos −/− mice compared with their expression in OT-II mice, after immunization with OVA (Fig. 4d) . These findings suggested that ligation of ICOS regulated OPN-i expression in CD4 + T cells activated in vivo.
Because activation of the PI(3)K signaling pathway is induced by ligation of ICOS 10 , we determined whether OPN-i associates with the p110 and p85 components of the PI(3)K complex. OPN-i did not interact with the p110α or p110δ subunits of PI(3)K in 293T human embryonic kidney cells transfected with plasmids encoding these proteins ( Supplementary Fig. 6a,b) . In addition, activation of PI(3)K and the kinase Akt, as indicated by phosphorylation of Akt, was not lower in OPN-KO CD4 + T cells stimulated with anti-CD3 and anti-ICOS than in OPN-i-KI CD4 + T cells stimulated similarly ( Supplementary  Fig. 6c) . Activation of IL-6 signaling, as indicated by phosphorylation of the transcription factors STAT1 and STAT3, was also not impaired in OPN-KO CD4 + T cells after incubation with IL-6 compared with that in IL-6-treated OPN-i-KI CD4 + T cells (Supplementary Fig. 6d ). However, OPN-i immunoprecipitated together with Flag-tagged p85α in 293T cells cotransfected with plasmids encoding these proteins (Fig. 4e) . In CD4 + T cells stimulated with anti-CD3, endogenous OPN-i interacted with p85α, and ligation of both CD3 and ICOS substantially increased their association (Fig. 4f) , which suggested that ICOS-dependent activation promoted the interaction between p85α and OPN-i.
Differentiation of T FH cells and T FR cells requires p85a
To determine whether p85α is required for the upregulation of Bcl-6 expression during T FH differentiation, we used mice with loxP-flanked alleles encoding p85α (Pi3kr1 fl/fl ) deleted by Cre recombinase expressed from the hematopoietic cell-specific Vav1 promoter (Pi3kr1 fl/fl Vav1-Cre + ; called 'p85α-KO' mice here). Three days after immunization of p85α-KO mice with KLH in CFA, the development of T FH cells and T FR cells, as well as Bcl-6 expression in these cells, was impaired in p85α-KO mice compared with that in Pi3kr1 fl/fl Vav1-Cre − mice ('p85α-wild-type' (p85α-WT)) (Supplementary Fig. 6e ). To specifically analyze the contribution of p85α to T FH differentiation, we transferred p85α-WT or p85α-KO naive CD4 + T cells together with wild-type B cells into Rag2 −/− Prf1 −/− hosts immunized with NP 26 -KLH in CFA. Despite the nearly normal population expansion and activation of the transferred p85α-KO CD4 + T cells following immunization ( Supplementary  Fig. 6f ), the frequency of p85α-KO Bcl-6 + CXCR5 + Foxp3 − CD4 + T FH cells was much lower and the anti-NP responses in adoptive hosts were impaired compared with those of hosts given transfer of p85α-WT CD4 + T cells (Fig. 5a and Supplementary Fig. 6g) . A lack of p85α in the Fig. 6h ). However, p85α deficiency significantly impaired the formation of T FR cells after the transfer of p85α-KO (CD45.2 + ) CD4 + T reg cells together with wild-type (CD45.1 + ) naive CD4 + T cells into Tcra −/− hosts immunized with NP 26 -KLH in CFA ( Fig. 5b and Supplementary Fig. 6g) . Recipients of p85α-KO CD4 + T reg produced larger amounts of total and high-affinity anti-NP than did recipients of p85α-WT CD4 + T reg cells (Fig. 5b) . Together these results indicated that p85α was required for the formation of T FH cells and T FR cells.
To further determine whether defective p85α expression diminished Bcl-6 expression, we transduced p85α-KO CD4 + T cells with retroviral vector expressing green fluorescent protein (GFP) alone (empty vector) or GFP plus a constitutively active form of Akt 27 , then sorted GFP + cells and transferred them, together with wild-type B cells, into Rag2 −/− Prf1 −/− hosts, followed by immunization of the hosts with NP 26 -KLH in CFA (Fig. 5c,d) . Among the GFP + p85α-KO CD4 + T cells, more cells transduced with the constitutively active Akt (~14%) than cells transduced with the empty vector (2%) contained phosphorylated Akt (Fig. 5c) . However, expression of constitutively active Akt did not significantly enhance the expression of Bcl-6 and CXCR5 in p85α-KO CD4 + T cells compared with that of cells transduced with empty vector (Fig. 5d and Supplementary Fig. 6g ). These findings indicated that p85α was required for the Bcl-6-dependent differentiation of T FH cells but p110 was not.
p85a chaperones the translocation of OPN-i to the nucleus Because the findings reported above suggested that p85α and OPN-i might contribute to Bcl-6-dependent differentiation of T FH cells, we sought to further define the interaction between p85α and OPN-i. SDS-PAGE analysis of lysates of 293T cells cotransfected with plasmids encoding Flag-tagged p85α and OPN-i showed that the p85α-bound fraction of OPN migrated more rapidly after treatment with phosphatases ( Supplementary Fig. 6i ), consistent with reports that p85α can recognize phosphorylated proteins. Through the use of the web-based motif-identifying program Scansite 28,29 , we identified a sequence in OPN (UniProt database accession code, P10923) near Tyr166 that might mediate interaction with the Src-homology 2 domain of p85α (Supplementary Fig. 6j) . Binding of the OPN-i mutant Y166F (with replacement of the tyrosine at position 166 with phenylalanine) to p85α was substantially reduced compared with the binding of wildtype OPN-i to p85α (Fig. 6a) , which suggested that the interaction of p85α with OPN-i required an intact Tyr166 site of OPN-i.
We next examined the cellular localization of OPN in CD44 + CD4 + T cells enriched from OPN-i-KI mice 3 d after immunization with KLH in CFA. Confocal microscopy revealed that Bcl-6 (stained with anti-Bcl-6 before labeling with a secondary fluorescence antibody) was mainly nuclear in Bcl-6 + cells (representing ~10% of CD44 + CD4 + T cells), and in vitro restimulation with anti-ICOS further increased the abundance of intranuclear Bcl-6 ( Fig. 6b and Supplementary  Fig. 6k ). While before stimulation with anti-ICOS, OPN-i was located mainly in the cytosol of Bcl-6 + CD4 + T cells, ligation of ICOS caused most OPN-i to migrate to the nucleus (Fig. 6b,c) . Because p85α can function as a chaperone to facilitate the translocation of associated partner proteins to the nucleus 15, 16 , we sought to determine whether p85α assisted in such translocation of OPN-i. In experiments in which 293T cells were cotransfected with plasmid encoding OPN-i and increasing concentrations of plasmid encoding Flag-tagged p85α, the accumulation of OPN-i in the nucleus increased in direct proportion to the amount of p85α (Fig. 6d) , and OPN did not relocate to the nucleus following ligation of ICOS in p85α-KO CD4 + T cells (Fig. 6e) . In addition, the mutant OPN-i Y166F remained mainly in the cytosol despite cotransfection with increasing concentrations of plasmid encoding p85α ( Fig. 6d and Supplementary Fig. 7a ). These findings suggest that the translocation of OPN-i to the nucleus was facilitated by a specific interaction between p85α and OPN-i. Immunoblot analysis of endogenous OPN-i among proteins immunoprecipitated with anti-Bcl-6 indicated that the two proteins interacted (Fig. 7a) . Cellular fractionation revealed that Bcl-6-OPN-i complexes were detectable only in the nucleus (Supplementary Fig. 7b ), consistent with the results of confocal microscopy ( Supplementary Fig. 7a ).
To specifically analyze the sequence(s) of Bcl-6 required for interaction with OPN-i, we constructed deletion mutants of Bcl-6, including deletion of sequences in the BTB domain, RD2 (second repression domain), PEST (Pro-Glu-Ser-Thr) domain or zinc-finger domain of Bcl-6 (Supplementary Fig. 7c ). Coimmunoprecipitation analysis of npg OPN-i and Flag-tagged wild-type or mutant Bcl-6 overexpressed in 293T cells indicated that sequences in RD2 of Bcl-6 (amino acids 120-300) were required for interaction with OPN-i, but those in the BTB, PEST and zinc-finger domains of Bcl-6 were not ( Fig. 7b and Supplementary Fig. 7c,d ). These findings indicated that intranuclear OPN-i might interact with Bcl-6. Because OPN-KO CD4 + T FH and T FR cells had lower expression of Bcl-6 protein than that of their OPN-i-KI counterparts at days 3-10 after immunization with KLH, we next investigated whether lack of OPN-i rendered Bcl-6 protein unstable. The addition of cycloheximide, which inhibits protein synthesis, to cultures of OT-II CD4 + T cells purified from mice 2.5 d after immmunization with OVA followed by stimulation in vitro with anti-CD3 and anti-ICOS, resulted in a greater reduction in Bcl-6 protein in OT-II OPN-KO CD4 + T cells (90%) than in their OT-II or OT-II OPN-i-KI counterparts (50%) (Fig. 7c) . In addition, overexpression of OPN-i prolonged the stability of Bcl-6 in cycloheximide-treated 293T cells (Fig. 7d) . The lower amount of Bcl-6 in all these cycloheximide-treated CD4 + T cells was 'rescued' by the addition of the proteasome inhibitor MG132 (Fig. 7c) , which suggested that the loss of Bcl-6 was proteasome dependent. Moreover, treatment with MG132 resulted in the appearance of highmolecular-mass species of Bcl-6 in the denatured extracts of these cells (Fig. 7e,f) . These high-molecular-mass forms of Bcl-6 were greater in abundance in the presence of overexpressed ubiquitin (Fig. 7e,f) , which suggested that they were ubiquitinated forms of Bcl-6. The addition of a 'pan-deubiquitination' inhibitor accelerated the degradation of Bcl-6 in wild-type, OPN-KO and OPN-i-KI CD4 + T cells, as well as in 293T cells transfected to express Flag-tagged Bcl-6 ( Fig. 7g and Supplementary Fig. 7e ). This effect was substantially prevented by OPN-i endogenously expressed in wild-type and Fig. 7g and Supplementary Fig. 7e ). These results suggested that OPN-i stabilized Bcl-6 through interference with the ubiquitin-mediated degradation of Bcl-6.
p85a-OPN-i interaction regulates T FH and T FR responses
To assess the physiological relevance of the p85α-OPN-i interaction to T FH differentiation, we transduced OT-II OPN-i-KI CD4 + T cells with retroviral vector expressing GFP alone (empty vector) or GFP plus either wild-type OPN-i or the OPN-i Y166F mutant, then transferred each group of cells together with wild-type B cells into Rag2 −/− Prf1 −/− hosts, followed by immunization of the hosts with NP 13 -OVA in CFA. We included OT-II OPN-KO CD4 + T cells transduced with empty vector as an additional control. T FH differentiation and the intracellular expression of Bcl-6 in these T FH cells, as assessed by flow cytometry, were substantially greater for OT-II OPN-i-KI CD4 + T cells transduced to express wild-type OPN-i than for these cells transduced with empty vector (Fig. 8a,b) . In contrast, expression of the OPN-i Y166F mutant in OT-II OPN-i-KI CD4 + T cells decreased Bcl-6 expression and T FH differentiation, similar to levels observed in OT-II OPN-KO CD4 + T cells transduced with empty vector (Fig. 8a,b) . We obtained similar results with a model in which we obtained CD4 + T cells from wild-type or OPN-KO mice immunized with type II collagen, transduced the cells with retroviral vector (as described above) and transferred the cells as sorted GFP + cells together with wild-type B cells into Rag2 −/− Prf1 −/− hosts, followed by immunization of the hosts with type II collagen in CFA. Expression of OPN-i Y166F in wild-type CD4 + T cells from mice immunized with type II collagen decreased the differentiation of these T cells into Bcl-6 + T FH cells and reduced the frequency of GL7 + B cells and autoantibody responses to collagen to levels observed in OPN-KO CD4 + T cells expressing GFP alone (transduced with empty vector) (Fig. 8c) . These results suggested that interaction between OPN-i and p85α was essential for the Bcl-6-dependent functional differentiation of T FH cells.
Using a retroviral reconstitution system similar to that described above, we also evaluated the physiological importance of the p85α-OPN-i interaction in the formation of T FR cells. We transduced CD45.2 + OPN-KO CD25 + CD4 + T cells with retroviral vector expressing GFP alone (empty vector) or GFP plus either wild-type OPN-i or mutant OPN-i Y166F, then transferred the cells as sorted GFP + cells together with CD45.1 + CD25 − CD4 + T cells and wild-type B cells into Rag2 −/− Prf1 −/− hosts, followed by immunization of the hosts with NP 26 -KLH in CFA. We included CD45.2 + OPN-i-KI CD25 + CD4 + T cells transduced with empty vector as an additional control. Expression of wild-type OPN-i in OPN-KO CD25 + CD4 + T cells markedly increaded T FR differentiation to levels similar to that of OPN-i-KI CD25 + CD4 + T cells expressing GFP alone (Fig. 8d) . In contrast,expression of OPN-i Y166F in OPN-KO CD25 + CD4 + T cells resulted in a substantially reduced frequency of Foxp3 + Bcl-6 + CXCR5 + T FR cells and an increase in GC B cells and the titers of anti-NP and antinuclear antibody (Fig. 8d,e) . Together these results indicated that a specific interaction between OPN-i and p85α was essential for sustained expression of Bcl-6 and functional differentiation of both T FH cells and T FR cells (Supplementary Fig. 8 ).
DISCUSSION
Signals from the receptor ICOS are essential for Bcl-6 expression and for the initiation and maintenance of T FH and T FR differentiation 5, 25, 26 . Here we defined p85α-OPN-i as a molecular link that coupled engagement of ICOS to sustained Bcl-6 expression and was essential for the differentiation of both T FH cells and T FR cells.
We found that ligation of ICOS induced interaction of the p85α component of PI(3)K with OPN-i, which promoted translocation of OPN-i to the nucleus and protection of Bcl-6 from ubiquitination-dependent degradation. Although the early steps of T FH differentiation that result in enhanced Bcl6 expression and the migration of follicular T cells depend on cytokines derived from activated DCs 30, 31 and might be independent of OPN-i expression, sustained Bcl-6 expression and full T FH and T FR differentiation require ICOS-dependent translocation of OPN-i and interaction with Bcl-6. Such findings indicate that TCR-ICOS signals known to be essential for the sustained differentiation of T FH cells and T FR cells preserve Bcl-6 expression in these cells, in contrast to bystander CD4 + cells that may undergo early cytokine-dependent activation by DCs but fail to activate an ICOS-p85α-OPN-i pathway required for stable Bcl-6 expression.
The activation of ICOS induces two distinct but overlapping PI(3)K signaling pathways. The catalytic ICOS-PI(3)K p110-Akt pathway can promote the migration of precursors of T FH cells into B cell follicles [11] [12] [13] 32 , while we have shown here that the ICOS-p85α-OPN-i pathway contributed to stable Bcl-6 expression and was essential for sustained follicular T cell responses. The division of labor between the two ICOS-linked PI(3)K pathways may depend in part on distinct environmental cues. Major histocompatibility complex class IIindependent, G protein-coupled signals may facilitate activation of the PI(3)K p110-Akt pathway 11, 12 , while engagement of the TCR and ICOS may promote the PI(3)K p85α-OPN-i pathway and sustained post-transcriptional Bcl-6 expression. TCR-ICOS signals may also indirectly regulate Bcl-6 expression by facilitating degradation of the transcription factor Foxo1 mediated by the E3 ubiquitin ligase Itch 33 . Additional studies are needed to define how these pathways are integrated into a functional T FH differentiation program. p85α also functions as a chaperone for translocation of the transcription factor XBP-1 to the nucleus after ligation of the insulin receptor 15, 16 . The relatively low intranuclear expression of p85α and its absence from OPN-i-Bcl-6 complexes would suggest that p85α might be released before OPN-i engages the intranuclear Bcl-6. The ability of the multifunctional adaptor OPN-i to interact with other intranuclear proteins to regulate gene expression by follicular T cells deserves further study 34 .
Our findings also indicated that an appropriate balance between T FH cells and T FR cells is critical for optimal GC responses to infection and avoidance of excessive or autoimmune responses that might result in host tissue destruction. Although T FH cells and T FR cells share many surface receptors and both require Bcl-6 expression, the molecular elements responsible for their differentiation within the GC follicles have remained unclear. Here we found that ICOS-dependent induction of OPN-i was required for sustained Bcl-6 expression in both follicular T cell subsets. The magnitude of the GC B cell selection and the associated antibody response depended on cognate interactions between T FH cells and antigen-specific B cells. Although OPN deficiency resulted in reduced T FR cell activity, defective T FH cell responses in the OPN-KO mice were not 'rescued' by decreased inhibitory activity of T FR cells. In contrast, selective impairment of OPN-i expression in T FR cells led to substantially increased antibody responses, including the development of high-affinity antibodies and autoantibodies, which indicated that the OPN-dependent protection of Bcl-6 expression in both follicular CD4 + T cell subsets was essential for control of the GC response.
The OPN-i and OPN-s isoforms arise from differences in translation of the same mRNA 17 . Although increased expression of Spp1 has been associated with T FH cell-associated autoimmune disorders and malignancies, the finding that intranuclear OPN contributed to lineage-specific T cell differentiation was unexpected. Mice that npg overexpress OPN develop a systemic autoimmune disorder 18 that resembles the phenotype of sanroque mice with mutations in the gene encoding roquin (Rc3h1), which result in part from dysregulated ICOS expression [35] [36] [37] . Intracellular OPN may promote excessive expression of IFN-α by plasmacytoid DCs and contribute to the population expansion of T H 17 cells in the context of systemic lupus erythematosus (SLE) 21, 23 . In support of the possibility of a role for OPN in the pathogenesis of SLE, expression of OPN in humans with SLE and autoimmune-prone (MRL-lpr/lpr) mice correlates with disease activity 38, 39 . Although high levels of circulating OPN-s may be a useful biomarker for SLE disease activity, separate analysis of OPN-i expression by CD4 + T FH cells and serum OPN may provide a more accurate assessment of SLE status. The finding that disruption of the ICOS-p85α-OPN-i pathway by overexpression of an OPN-i mutant inhibited T FH cell responses and associated autoantibody production also suggests that targeting the p85α-OPN-i interaction might allow inhibition of T FH cell responses and amelioration of systemic autoimmune disease.
Our results also suggest a requirement for continued protection of Bcl-6 protein from ubiquitination and proteosomal degradation. Bcl-6 represses a group of genes that control lymphocyte differentiation and cell division 4, 40 . Studies of Bcl-6 expression by normal and neoplastic GC B cells have also suggested that Bcl-6 is highly sensitive to post-translational breakdown 4 . Our findings indicated that overexpression of OPN-i leading to enhanced levels of OPN-i-Bcl-6 complexes might result in increased Bcl-6 expression and enhanced T FH cell responses. Indeed, overexpression of OPN and localization of OPN to the nucleus are associated with aggressive T FH cell-like lymphomas and poor prognosis 41, 42 .
We found that OPN-i interacted with RD2 of Bcl-6 to inhibit its ubiquitination-mediated degradation in follicular T cells. A similar interaction between the heat-shock protein hsp90 and RD2 of Bcl-6 protects Bcl-6 from proteasomal degradation in neoplastic GC B cells 4, 43 . Inhibition of hsp90 expression or mutation of sequence encoding the BTB domain of Bcl-6 impairs the survival of normal and neoplastic GC B cells but spares the differentiation of T FH cells 4, [43] [44] [45] . We found that inhibition of OPN-i expression did not affect B cell activity. Excessive Bcl-6 expression might be inhibited by drugs that inhibit post-translational Bcl-6 metabolism 46 , including those that target the p85α-OPN-i interaction defined here. Drugs that target the OPN-i-Bcl-6 and hsp90-Bcl-6 interactions differently may also allow separate control of follicular T cell responses and GC B cell responses.
Our findings also have a bearing on efforts to define the plasticity and diversity of T FH cells through accurate analysis of Bcl-6 protein in CD4 + T cells. Although expression of Bcl-6 protein returned to basal levels by 2 weeks after immunization, Bcl6 mRNA expression remained elevated in putative T FH cells. Precise definition of the T FH cell response, as well as its relationship to other helper T cell subsets, may require coordinated measurements of both Bcl-6 protein and Bcl6 mRNA. In sum, the observations that intranuclear OPN-i protected Bcl-6 from proteasome-associated degradation and allowed sustained Bcl-6 expression in T FH cells and T FR cells provide new insight into the ICOS-dependent differentiation of T FH cells and T FR cells and suggest new therapeutic avenues for manipulating the GC response.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. GEO: microarray data, GSE61284. 
